Brian Pomper Quoted by Chemical & Engineering News on TPP IP Protection Plan for Biologics
Chemical & Engineering News, for its article “Trans-Pacific trade pact faces rocky road,” quoted Akin Gump public law and policy partner Brian Pomper on the Trans-Pacific Partnership (TPP)’s plan for biologic medicines regarding intellectual property protection.
According to the article, currently, nations within the TPP have a variety of different approaches regarding the length of market protections for biologics ranging from 12 years to having no protection at all. Negotiators recently agreed upon a deal that allows the U.S. to keep its current 12-year standard while requiring other nations to adopt a five- to eight-year protection period—a decision that has been met with opposition by several of the TPP countries.
Of the deal, Pomper said, “there is no way TPP will pass without some significant accommodations on the biopharmaceutical side.”